File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: HGF/MET signaling in ovarian cancer

TitleHGF/MET signaling in ovarian cancer
Authors
KeywordsHGF
MET
OSE
Ovarian cancer
Issue Date2008
PublisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cmm/index.htm
Citation
Current Molecular Medicine, 2008, v. 8 n. 6, p. 469-480 How to Cite?
AbstractOvarian cancer is the leading cause of death from gynecological cancers in North America and Eurorope. Despite its clinical significance, the factors that regulate the development and progression of ovarian cancer are among the least understood of all major human malignancies. A growth factor with pleiotropic effects, which has attracted increasing attention in recent years, is the hepatocyte growth factor (HGF) and its receptor MET. While deregulated HGF/MET signaling is observed in many tumors, the consequences of MET activation are complex and context dependent. Recent observations have demonstrated a cross-talk of other signaling pathways with MET signaling. This review summarizes the key findings and recent advances in our understanding of HGF and MET in the transformation and progression of ovarian cancer. We will begin with a brief discussion on the role of HGF and MET in the physiology of normal ovarian surface epithelium (OSE) and ovarian cancer development. In particular, the coexpression of HGF and MET in OSE of women with hereditary ovarian cancer syndromes emphasizes their importance in neoplastic transformation of OSE. The involvement of HGF in other aspects of tumor progression, such as invasion and metastasis, and novel downstream target genes activated by HGF is summarized next. The therapeutic potential of HGF to treat ovarian cancer and to improve response to conventional chemotherapy is also described. Finally, the most recent progress in drug development and future areas of research in terms of their potential clinical implications are discussed. © 2008 Bentham Science Publishers Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/89292
ISSN
2015 Impact Factor: 2.912
2015 SCImago Journal Rankings: 1.574
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorZhou, HYen_HK
dc.contributor.authorPon, YLen_HK
dc.contributor.authorWong, ASTen_HK
dc.date.accessioned2010-09-06T09:55:01Z-
dc.date.available2010-09-06T09:55:01Z-
dc.date.issued2008en_HK
dc.identifier.citationCurrent Molecular Medicine, 2008, v. 8 n. 6, p. 469-480en_HK
dc.identifier.issn1566-5240en_HK
dc.identifier.urihttp://hdl.handle.net/10722/89292-
dc.description.abstractOvarian cancer is the leading cause of death from gynecological cancers in North America and Eurorope. Despite its clinical significance, the factors that regulate the development and progression of ovarian cancer are among the least understood of all major human malignancies. A growth factor with pleiotropic effects, which has attracted increasing attention in recent years, is the hepatocyte growth factor (HGF) and its receptor MET. While deregulated HGF/MET signaling is observed in many tumors, the consequences of MET activation are complex and context dependent. Recent observations have demonstrated a cross-talk of other signaling pathways with MET signaling. This review summarizes the key findings and recent advances in our understanding of HGF and MET in the transformation and progression of ovarian cancer. We will begin with a brief discussion on the role of HGF and MET in the physiology of normal ovarian surface epithelium (OSE) and ovarian cancer development. In particular, the coexpression of HGF and MET in OSE of women with hereditary ovarian cancer syndromes emphasizes their importance in neoplastic transformation of OSE. The involvement of HGF in other aspects of tumor progression, such as invasion and metastasis, and novel downstream target genes activated by HGF is summarized next. The therapeutic potential of HGF to treat ovarian cancer and to improve response to conventional chemotherapy is also described. Finally, the most recent progress in drug development and future areas of research in terms of their potential clinical implications are discussed. © 2008 Bentham Science Publishers Ltd.en_HK
dc.languageengen_HK
dc.publisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cmm/index.htmen_HK
dc.relation.ispartofCurrent Molecular Medicineen_HK
dc.subjectHGFen_HK
dc.subjectMETen_HK
dc.subjectOSEen_HK
dc.subjectOvarian canceren_HK
dc.titleHGF/MET signaling in ovarian canceren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1566-5240&volume=8&spage=469&epage=480&date=2008&atitle=HGF/MET+signaling+in+ovarian+canceren_HK
dc.identifier.emailWong, AST: awong1@hkucc.hku.hken_HK
dc.identifier.authorityWong, AST=rp00805en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2174/156652408785747933en_HK
dc.identifier.pmid18781954en_HK
dc.identifier.scopuseid_2-s2.0-53149116692en_HK
dc.identifier.hkuros144166en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-53149116692&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume8en_HK
dc.identifier.issue6en_HK
dc.identifier.spage469en_HK
dc.identifier.epage480en_HK
dc.identifier.isiWOS:000259446600003-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridZhou, HY=24802759600en_HK
dc.identifier.scopusauthoridPon, YL=22235406500en_HK
dc.identifier.scopusauthoridWong, AST=23987963300en_HK
dc.identifier.citeulike3207134-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats